Merck is pausing shipments of its Gardasil vaccine to China due to a 17% drop in sales, attributed to lower demand. The pause follows recent approval for the vaccine's use in males in China. Merck's earnings expectations for 2025 are lower than analysts' projections, and shares dropped 8% in pre-market trading. Vollständiger Artikel (Euronews.com)